Biotech's Next Breakthrough? Clinical Trial Abundance w/ Ruxandra Tesloianu

Biology is booming, so why isn’t medicine keeping up?

We sit down with Ruxandra Tesloianu to unpack the real constraints slowing drug development. From clinical trial inefficiencies and regulatory opacity to risk-averse biotech culture, we explore why breakthrough discoveries so often stall before reaching patients, and why increasing the availability of clinical trials might be the answer.

We dig into:

•⁠  ⁠Why pharma R&D productivity keeps falling (Eroom’s Law)
•⁠  ⁠The clinical trial bottleneck and late human feedback loops
•⁠  ⁠How regulatory uncertainty quietly inflates costs
•⁠  ⁠Why investors avoid high-risk areas like aging
•⁠  ⁠The overlooked role of surrogate endpoints and biomarkers
•⁠  ⁠What China and Australia reveal about regulatory arbitrage
•⁠  ⁠Whether AI can actually fix the pipeline
•⁠  ⁠The expanding role of IRBs and procedural friction

Follow & Support Everybody Gets Pie
X: @pie4everybody
Bluesky: @everybodygetspie.bsky.social
YouTube: @EverybodyGetsPie
Instagram: @everybodygetspie
TikTok: @everybodygetspie

🎙️ Subscribe, share, and let us know who you’d like to hear on the next episode!